The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
Open accessAbstract
AIMS: This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD). METHODS AND RESULTS: Subjects (n=101) were randomly assigned to the following loading dose (LD) (day 1)/maintenance dose (MD) (days 2-28) combinations: prasugrel, 40 mg/5 mg; 40 mg/7.5 mg; 60 mg/10 mg; 60 mg/15 mg; or clopidogrel, 300 mg/75 mg. Turbidometric platelet aggregation was measured at multiple timepoints during the study. At 4 h after dosing, with 20 microM ADP, both prasugrel LDs achieved significantly higher mean IPA levels (60.6% and 68.4 vs. 30.0%, respectively; all P<0.0001) and lower percentage (3 vs. 52%, P<0.0001) of pharmacodynamic non-responders (defined as IPA <20%) than clopidogrel. Prasugrel 10 and 15 mg MDs achieved consistently higher mean IPA than clopidogrel 75 mg at day 28 (all P<0.0001). At pre-MD on day 28, there were no non-responders in the 10 and 15 mg prasugrel group, compared with 45% in the clopidogrel group (P=0.0007). CONCLUSION: In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials
Cutlip, D. E., Baim, D. S., Ho, K. K. L., Popma, J. J., Lansky, A. J., Cohen, D. J., Carrozza, J. P., Chauhan, M. S., Rodriguez, O., & Kuntz, R. E. (2001) · Circulation · doi:10.1161/01.cir.103.15.1967 · Cited by 855
Müller, I., Besta, F., Schulz, C., Massberg, S., Schönig, A., & Gawaz, M. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613462 · Cited by 585
Barragan, P., Bouvier, J., Roquebert, P., Macaluso, G., Commeau, P., Comet, B., Lafont, A., Camoin, L., Walter, U., & Eigenthaler, M. (2003) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.10497 · Cited by 434
Fontana, P., Dupont, A., Gandrille, S., Bachelot-Loza, C., Reny, J.-L., Aiach, M., & Gaussem, P. (2003) · Circulation · doi:10.1161/01.cir.0000085073.69189.88 · Cited by 425
MÜLLER, I., SEYFARTH, M., RÜDIGER, S., WOLF, B., POGATSA-MURRAY, G., SCHÖMIG, A., & GAWAZ, M. (2001) · Heart · doi:10.1136/heart.85.1.92 · Cited by 405
Hochholzer, W., Trenk, D., Frundi, D., Blanke, P., Fischer, B., Andris, K., Bestehorn, H.-P., Büttner, H. J., & Neumann, F. (2005) · Circulation · doi:10.1161/01.cir.0000160869.75810.98 · Cited by 398
Cited by
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,308
Variability in Individual Responsiveness to Clopidogrel
Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T. A., & Costa, M. A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.044 · Cited by 959
Metadata
- Authors
- Jernberg, T., Payne, C. D., Winters, K. J., Darstein, C., Brandt, J. T., Jakubowski, J. A., Naganuma, H., Siegbahn, A., & Wallentin, L.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-04-18
- Volume
- 27
- Issue
- 10
- Pages
- 1166-1173
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2116457054
- Cited by
- 538
- References
- 19
- FWCI
- 38.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. https://app.cochat.ai/papers/10.1093/eurheartj/ehi877
- The paper
- Jernberg, T., Payne, C. D., Winters, K. J., Darstein, C., Brandt, J. T., Jakubowski, J. A., Naganuma, H., Siegbahn, A., & Wallentin, L. (2006). Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi877
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
